Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study

To compare the real-world safety profile of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors between younger and older patients. All patients receiving pembrolizumab, nivolumab, atezolizumab or durvalumab between September 2016 and September 2019 at Haga Teaching...

Full description

Bibliographic Details

Published in:	Journal of geriatric oncology 2022-09, Vol.13 (7), p.997-1002
Main Authors:	Storm, Bert N., Abedian Kalkhoran, Hanieh, Wilms, Erik B., Brocken, Pepijn, Codrington, Henk, Houtsma, Danny, Portielje, Johanneke E.A., de Glas, Nienke, van der Ziel, Daisy, van den Bos, Frederiek, Visser, Loes E.
Format:	Article
Language:	English
Subjects:	Adverse drug reactions Elderly Immune checkpoint inhibitors PD-1 inhibitors PD-L1 inhibitors Real-world data Safety
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!